
    
      Patients with a diagnosis of early-stage uterine leiomyosarcoma have a 70% chance of relapse
      or recurrence of their disease. Patients enrolled in this trial will receive 4 cycles of
      gemcitabine and docetaxel followed by 4 cycles of adriamycin. Following completion of
      chemotherapy, they will be have repeat imaging at regular intervals to monitor for disease
      recurrence along with periodic clinical evaluations.
    
  